Banner image of hundreds of different-colored cells

What We Do

Harness the specificity of CRISPR to refine your NGS library with CRISPRclean®

~66% of the human genome is repetitive DNA ~90% of reads from a single cell data set are noise >90% of reads from RNA seq data are abundant ribosomal, mitochondrial or housekeeping genes

The ability to sequence millions of reads from genomes and transcriptomes has yielded an unprecedented discovery on genes and genetic variation. Unfortunately, much of these reads are wasted on over abundant sequences that are captured repeatedly.

Future discovery may be accelerated by cutting through the noise of over abundant sequences. Shifting focus away from abundant genes and increasing sensitivity by lowering background noise is required to enable this discovery. It’s why we created CRISPRclean.

CRISPRclean technology harnesses the specificity of CRISPR-Cas9 to degrade abundant, uninformative sequences in next-generation sequencing (NGS) libraries. With CRISPRclean, you can see more lower expressing transcripts and shift your sequencing power for deeper coverage and improved signal.

Now you can see exactly what you want, breaking through the clutter—and breaking new ground.

Benefits of CRISPRclean technology

Highly programmable

Increased sensitivity

Simple automatable workflow

Genomic analysis
platform agnostic

How CRISPRclean works

CRISPRclean mediated depletion can be integrated directly into NGS library prep protocols at various points depending on the application. CRISPR-Cas9 complexes are formed with a pool of designed guide RNAs. After targeted sequences are cut, they cannot be a substrate for PCR amplification or subsequent sequencing. The output is a refined, sequence ready NGS library.

Diagram showing how CRISPRclean works


CRISPRclean technology is both specific and highly programmable to remove unwanted sequences for many applications.
View the applications below to learn how Jumpcode is driving discovery today.

Single Cell Analysis

Gain a deeper view of expression profiles of individual cells

Learn More


Characterize microbial populations and their impact on human health

Learn More

Infectious Disease Surveillance

Detect known and novel pathogens to accelerate outbreak investigations

Learn More

Whole Transcriptome Profiling

Measure gene and transcript activity to interrogate gene expression patterns

Learn More

Customer Story – ImYoo

Isolating informative RNA gives ImYoo™ greater power to grow their business.

ImYoo is a single-cell transcriptomics startup that helps biopharma companies stratify study participants to optimize clinical trials. The company is using single-cell gene expression profiling to understand immune variability and personalize information.

Read More All Customer Stories
Imyoo's Logo

For the US patent, the patent number is US 10,604,802 entitled Genome Fractioning. The patent publication is available here.

For the EP patent, the patent number is EP3102722 entitled Genome Fractioning. The patent publication is available here.